amended, an investigation be instituted to determine whether there is a violation of subsection (a)(1)(B) of section 337 in the importation into the United States, the sale for importation, or the sale within the United States after importation of certain products identified in paragraph (2) by reason of infringement of one or more of claims 1, 2, 5–11, 14, 15, 17, 18, 20, 21, 23, 25, 26, 28, 29, 31, and 33 of the '273 patent and claims 2, 5–11, 14, 15, 17, 18, 20, 22, and 23 of the '685 patent; claims 1–6, 8–10, and 11–19 of the '118 patent, and whether an industry in the United States exists or is in the process of being established as required by subsection (a)(2) of section 337.

(2) Pursuant to section 210.10(b)(1) of the Commission’s Rules of Practice and Procedure, 19 CFR 210.10(b)(1), the plain language description of the accused products or category of accused products, which defines the scope of the investigation, is “(1) certain smart thermostat devices that serve as in-unit hubs for the remote control of smart door locks, (2) systems including those smart thermostat devices, and (3) internal circuitry, printed circuit boards, and communication components for those smart thermostat devices.”

(3) For the purpose of the investigation so instituted, the following are hereby named as parties upon which this notice of investigation shall be served:

(a) The complainants are:
EDST, LLC, 5214 68th Street, Suite 402, Lubbock, TX 79424
Quext IoT, LLC, 5214 68th Street, Suite 201, Lubbock, TX 79424

(b) The respondents are the following entities alleged to be in violation of section 337, and are the parties upon which the complaint is to be served:

iApartments, Inc., 201 E Kennedy Blvd., Suite 1925, Tampa, FL 33602
Hsun Wealth Technology Co., Ltd., 11th Floor, No. 47, Qingpu, Qingpu Village, Zhongli District, Taoyuan City, 32056, Taiwan
Huarifu Technology Co., Ltd., 11th Floor, No. 49, Section 1, Qingfeng Road, Zhongli District, Taoyuan City, 32056, Taiwan

(4) For the investigation so instituted, the Chief Administrative Law Judge, U.S. International Trade Commission, shall designate the presiding Administrative Law Judge. The Office of Unfair Import Investigations will not be participating as a party in this investigation.

Responses to the complaint and the notice of investigation must be submitted by the named respondents in accordance with section 210.13 of the Commission’s Rules of Practice and Procedure, 19 CFR 210.13. Pursuant to 19 CFR 201.16(e) and 210.13(a), as amended in 85 FR 15798 (March 19, 2020), such responses will be considered by the Commission if received not later than 20 days after the date of service by the complainants of the complaint and the notice of investigation. Extensions of time for submitting responses to the complaint and the notice of investigation will not be granted unless good cause therefor is shown.

Failure of a respondent to file a timely response to each allegation in the complaint and in this notice may be deemed to constitute a waiver of the right to appear and contest the allegations of the complaint and this notice, and to authorize the administrative law judge and the Commission, without further notice to the respondent, to find the facts to be as alleged in the complaint and this notice and to enter an initial determination and a final determination containing such findings, and may result in the issuance of an exclusion order or a cease and desist order or both directed against the respondent.

By order of the Commission.
Issued: October 18, 2022.

Jessica Mullan,
Attorney Advisor.

[FR Doc. 2022–22998 Filed 10–21–22; 8:45 am]
BILLING CODE 7020–02–P

INTERNATIONAL TRADE COMMISSION
[Investigation Nos. 701–TA–557 and 731–TA–1316 (Review)]

Stainless Steel Sheet and Strip From China: Scheduling of Expedited Five-Year Reviews


ACTION: Notice.

SUMMARY: The Commission hereby gives notice of the scheduling of expedited reviews pursuant to the Tariff Act of 1930 (“the Act”) to determine whether revocation of the countervailing and antidumping duty orders on 1-hydroxyethylidene-1,1-diphosphonic acid (HEDP) from China is likely to lead to continuation or recurrence of material injury within a reasonably foreseeable time.

DATES: July 5, 2022.


1-Hydroxyethylidene-1, 1-Diphosphonic Acid (HEDP) From China: Scheduling of Expedited Five-Year Reviews

1 The record is defined in § 207.2(f) of the Commission’s Rules of Practice and Procedure (19 CFR 207.2(f)).
SUPPLEMENTARY INFORMATION:
Background.—On July 5, 2022, the Commission determined that the domestic interested party group response to its notice of institution (87 FR 19125, April 1, 2022) of the subject five-year reviews was adequate and that the respondent interested party group response was inadequate. The Commission did not find any other response was inadequate. The respondent interested party group (supplemental reviews, the deadline for comments pursuant to section 751(c)(3) of the Tariff Act of 1930 (19 U.S.C. 1675(c)(3)).

For further information concerning the conduct of these reviews and rules of general application, consult the Commission’s Rules of Practice and Procedure, part 201, subparts A and B (19 CFR part 201), and part 207, subparts A, D, E, and F (19 CFR part 207).

Staff report.—A staff report containing information concerning the subject matter of the reviews has been placed in the nonpublic record, and will be made available to persons on the Administrative Protective Order service list for these reviews on October 19, 2022. A public version will be issued thereafter, pursuant to §207.62(d)(4) of the Commission’s rules.

Written submissions.—As provided in §207.62(d) of the Commission’s rules, interested parties that are parties to the reviews and that have provided individually adequate responses to the notice of institution,2 and any party other than an interested party to the reviews may file written comments with the Secretary on what determination the Commission should reach in the reviews. Comments are due on or before October 26, 2022 and may not contain new factual information. Any person that is neither a party to the five-year reviews nor an interested party may submit a brief written statement (which shall not contain any new factual information) pertinent to these reviews by October 26, 2022. However, the Department of Commerce (“Commerce”) shall extend the time limit for its completion of the final results of its reviews, the deadline for comments (which may not contain new factual information) on Commerce’s final results is three business days after the issuance of Commerce’s results. If comments contain business propriety information (BPI), they must conform with the requirements of §§201.6, 207.3, and 207.7 of the Commission’s rules. The Commission’s Handbook on Filing Procedures, available on the Commission’s website at https://www.usitc.gov/documents/handbook_on_filing_procedures.pdf, elaborates upon the Commission’s procedures with respect to filings.

In accordance with §§201.16(c) and 207.3 of the rules, each document filed by a party to the reviews must be served on all other parties to the reviews (as identified by either the public or BPI service list), and a certificate of service must be timely filed. The Secretary will not accept a document for filing without a certificate of service.

Determination.—The Commission has determined these reviews are extraordinarily complicated and therefore has determined to exercise its authority to extend the review period by up to 90 days pursuant to 19 U.S.C. 1675(c)(3)(B).

Authority: These reviews are being conducted under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to §207.62 of the Commission’s rules.

By order of the Commission.
Issued: October 18, 2022.

Jessica Mullan,
Attorney Advisor.

[FR Doc. 2022–23000 Filed 10–21–22; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE
Drug Enforcement Administration

[Docket No. DEA–1103]
Importer of Controlled Substances Application: Fisher Clinical Services, Inc.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Fisher Clinical Services, Inc., has applied to be registered as an importer of basic class(es) of controlled substance(s):

<table>
<thead>
<tr>
<th>Controlled substance</th>
<th>Drug code</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psilocybin</td>
<td>7437</td>
<td>I</td>
</tr>
<tr>
<td>Marijuana Extract</td>
<td>7350</td>
<td>I</td>
</tr>
<tr>
<td>Methylphenidate</td>
<td>1724</td>
<td>II</td>
</tr>
<tr>
<td>Levorphanol</td>
<td>9220</td>
<td>II</td>
</tr>
<tr>
<td>Noroxycphene</td>
<td>9668</td>
<td>II</td>
</tr>
<tr>
<td>Tapentadol</td>
<td>9780</td>
<td>II</td>
</tr>
</tbody>
</table>

The company plans to import the listed controlled substances for clinical trials only. No other activities for these drug codes are authorized for this registration.

Address: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on September 20, 2022, Fisher Clinical Services, Inc., 7554 Schantz Road, Allentown, Pennsylvania 18106–9032, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

1 A record of the Commissioners’ votes, the Commission’s statement on adequacy, and any individual Commissioner’s statements will be available from the Office of the Secretary and at the Commission’s website.
2 The Commission has found the response submitted by Compass Chemical International, LLC, a domestic producer, to be individually adequate. Comments from other interested parties will not be accepted (see 19 CFR 207.62(d)(2)).